91182-60-4

Basic information

• Product Name: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid
• Synonyms: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid;4-Isoxazolecarboxylic acid, 5-(4-broMophenyl)-3-Methyl-;5-(4-Bromophenyl)-3-methyl-4-isoxazolecarboxylic acid;5-(p-Bromophenyl)-3-methyl-4-isoxazolecarboxylic acid;EOS-60371
• CAS NO: 91182-60-4
• Molecular Formula: C₁₁H₈BrNO₃
• Molecular Weight: 282.09012
• Mol File: 91182-60-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 409℃
• Flash Point: 201℃
• Appearance: /
• Density: 1.605
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid(91182-60-4)
• EPA Substance Registry System: 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid(91182-60-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 91182-60-4(Hazardous Substances Data)

Usage

General Description

5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid is a chemical compound with the molecular formula C10H8BrNO3. It is a derivative of isoxazole and carboxylic acid and contains a 4-bromophenyl and a 3-methyl substituent. 5-(4-Bromo-phenyl)-3-methyl-isoxazole-4-carboxylic acid is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also being researched for its potential pharmacological properties, including anti-inflammatory and antifungal activities. Additionally, it has been studied for its potential in the treatment of neurological disorders and as a possible component in the development of new medications.

InChI:InChI=1S/C11H8BrNO3/c1-6-9(11(14)15)10(16-13-6)7-2-4-8(12)5-3-7/h2-5H,1H3,(H,14,15)

Upstream product

• 893643-73-7 2-(4-bromobenzoyl)-3-carbonylbutyrate ethyl ester 
• 1423699-80-2 C₁₃H₁₄BrNO₃ 
• 586-75-4 4-chlorobenzoyl chloride 
• 586-76-5 4-Bromobenzoic acid 
• 85963-90-2 methyl 2-(4-bromobenzoyl)-3-oxo-butanoate 
• 1228689-61-9 methyl 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylate 
• 917388-58-0 5-(4-bromophenyl)-3-methylisoxazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1280205-93-7 5-(4-bromo-phenyl)-3-methyl-isoxazol-4-ylamine 
• 1280206-00-9 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-(3-phenyl-propyl)-amine 
• 1280206-03-2 [5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-[3-(4-isopropyl-phenyl)-2-methyl-propyl]-amine 
• 1280208-00-5 2-benzylsulfanyl-1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]-ethanone 
• 1280208-02-7 2-Bromo-1-[5-(4-bromo-phenyl)-3-methyl-isoxazol-4-yl]ethanone 
• 1228690-36-5 AM₀₉₅ 
• 1228690-38-7 {4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-acetic acid ethyl ester 
• 1345614-59-6 (2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic acid) sodium salt 
• 1280205-98-2 (5-(4-bromophenyl)-3-methylisoxazole-4-yl)methanol 
• 1380650-63-4 1-{4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid ethyl ester 

Relevant articles and documents

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF

Described herein is the LPA1 antagonist 1- {4'-[3-methyl-4-((R)- l-phenyl-ethoxycarbonylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing t

POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.